172 related articles for article (PubMed ID: 26514537)
1. Application of a Non-Mixture Cure Rate Model for Analyzing Survival of Patients with Breast Cancer.
Baghestani AR; Moghaddam SS; Majd HA; Akbari ME; Nafissi N; Gohari K
Asian Pac J Cancer Prev; 2015; 16(16):7359-63. PubMed ID: 26514537
[TBL] [Abstract][Full Text] [Related]
2. Survival Analysis of Patients with Breast Cancer using Weibull Parametric Model.
Baghestani AR; Moghaddam SS; Majd HA; Akbari ME; Nafissi N; Gohari K
Asian Pac J Cancer Prev; 2015; 16(18):8567-71. PubMed ID: 26745118
[TBL] [Abstract][Full Text] [Related]
3. Comparison Cure Rate Models by DIC Criteria in Breast Cancer Data.
Baghestani AR; Shahmirzalou P; Sayad S; Akbari ME; Zayeri F
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1601-1606. PubMed ID: 29936785
[TBL] [Abstract][Full Text] [Related]
4. Fitting Cure Rate Model to Breast Cancer Data of Cancer Research Center.
Baghestani AR; Zayeri F; Akbari ME; Shojaee L; Khadembashi N; Shahmirzalou P
Asian Pac J Cancer Prev; 2015; 16(17):7923-7. PubMed ID: 26625822
[TBL] [Abstract][Full Text] [Related]
5. Estimation of the cure rate in Iranian breast cancer patients.
Rahimzadeh M; Baghestani AR; Gohari MR; Pourhoseingholi MA
Asian Pac J Cancer Prev; 2014; 15(12):4839-42. PubMed ID: 24998549
[TBL] [Abstract][Full Text] [Related]
6. Assessment of prognostic factors in long-term survival of male and female patients with colorectal cancer using non-mixture cure model based on the Weibull distribution.
Azizmohammad Looha M; Zarean E; Masaebi F; Pourhoseingholi MA; Zali MR
Surg Oncol; 2021 Sep; 38():101562. PubMed ID: 33862578
[TBL] [Abstract][Full Text] [Related]
7. Survival probability and prognostic factors of Iranian breast cancer patients using cure rate model.
Meshkat M; Baghestani AR; Zayeri F; Khayamzadeh M; Akbari ME
Breast J; 2018 Nov; 24(6):1015-1018. PubMed ID: 30270522
[TBL] [Abstract][Full Text] [Related]
8. Analyzing Survival Rate of Leukemia Patients Applying Long Term Exponential Model.
Faridizadeh M; Alavi Majd H; Parkhideh S; Hajifathali A; Raei M; Ramezani N; Saeedi A; Baghestani AR
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1539-1543. PubMed ID: 32592346
[TBL] [Abstract][Full Text] [Related]
9. Invasive Pleomorphic Lobular Histology Is an Adverse Prognostic Factor on Survival in Patients with Breast Cancer.
Sahin S; Karatas F; Erdem GU; Hacioglu B; Altundag K
Am Surg; 2017 Apr; 83(4):359-364. PubMed ID: 28424130
[TBL] [Abstract][Full Text] [Related]
10. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.
Chang JM; McCullough AE; Dueck AC; Kosiorek HE; Ocal IT; Lidner TK; Gray RJ; Wasif N; Northfelt DW; Anderson KS; Pockaj BA
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S509-15. PubMed ID: 26001860
[TBL] [Abstract][Full Text] [Related]
11. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for survival in patients with breast cancer referred to Cancer Research Center in Iran.
Baghestani AR; Shahmirzalou P; Zayeri F; Akbari ME; Hadizadeh M
Asian Pac J Cancer Prev; 2015; 16(12):5081-4. PubMed ID: 26163645
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis in a Chinese population with T1-2N1 breast cancer: Did patients with 1 or 2, and 3 positive axillary lymph nodes have similar survival outcomes?
Shen H; Yuan J; Yang Y; Liu X; Wang L; Feng X; Zhao L; Niu Y
J Surg Oncol; 2015 Nov; 112(6):569-74. PubMed ID: 26458282
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
[TBL] [Abstract][Full Text] [Related]
15. Exploring factors related to metastasis free survival in breast cancer patients using Bayesian cure models.
Jafari-Koshki T; Mansourian M; Mokarian F
Asian Pac J Cancer Prev; 2014; 15(22):9673-8. PubMed ID: 25520087
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of Extracapsular Invasion at Sentinel Lymph Nodes in Breast Cancer Patients with Sentinel Lymph Node Involvement.
Shigematsu H; Taguchi K; Koui H; Ohno S
Ann Surg Oncol; 2015 Jul; 22(7):2365-71. PubMed ID: 25476029
[TBL] [Abstract][Full Text] [Related]
18. Type of breast cancer diagnosis, screening, and survival.
Cedolini C; Bertozzi S; Londero AP; Bernardi S; Seriau L; Concina S; Cattin F; Risaliti A
Clin Breast Cancer; 2014 Aug; 14(4):235-40. PubMed ID: 24703317
[TBL] [Abstract][Full Text] [Related]
19. Cure models for estimating hospital-based breast cancer survival.
Rama R; Swaminathan R; Venkatesan P
Asian Pac J Cancer Prev; 2010; 11(2):387-91. PubMed ID: 20843121
[TBL] [Abstract][Full Text] [Related]
20. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
Sinha AK; Patel JR; Shen Y; Ueno NT; Giordano SH; Tripathy D; Lopez DS; Barcenas CH
PLoS One; 2017; 12(1):e0170081. PubMed ID: 28085940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
